Champions Oncology, Inc. (CSBR) financial statements (2021 and earlier)

Company profile

Business Address 855 N. WOLFE STREET
BALTIMORE, MD 21205
State of Incorp. DE
Fiscal Year End April 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7831339
Cash and cash equivalents7831339
Receivables6544212
Other undisclosed current assets000000(0)
Total current assets:1413856411
Noncurrent Assets
Operating lease, right-of-use asset53
Property, plant and equipment6432110
Intangible assets, net (including goodwill)0011111
Goodwill0011111
Restricted cash and investments   0000
Other noncurrent assets00000  
Total noncurrent assets:11733211
TOTAL ASSETS:25211188612
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4643322
Accounts payable2332221
Accrued liabilities2311100
Deferred revenue76
Debt 10    
Deferred revenue and credits5532
Other undisclosed current liabilities1 4    
Total current liabilities:111287754
Noncurrent Liabilities
Long-term debt and lease obligation63 000 
Capital lease obligations 000 
Operating lease, liability63
Liabilities, other than long-term debt, including:0000000
Deferred rent credit  1
Other liabilities0001000
Other undisclosed liabilities, other than long-term debt  (1)(0)(0)(0)(0)
Other undisclosed noncurrent liabilities  10000
Total noncurrent liabilities:6311000
Total liabilities:171598864
Stockholders' equity
Stockholders' equity attributable to parent8520008
Common stock0000000
Treasury stock, value   (1)(1)(1)(1)
Additional paid in capital80787372716461
Accumulated deficit(72)(73)(71)(71)(69)(62)(52)
Total stockholders' equity:8520008
TOTAL LIABILITIES AND EQUITY:25211188612

Income statement (P&L) ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
Revenues3932272015119
Revenue, net2015119
Cost of revenue
(Cost of Goods and Services Sold)
(16)      
Other undisclosed gross profit12      
Gross profit:3532272015119
Operating expenses(40)(34)(27)(22)(22)(21)(22)
Other undisclosed operating income4      
Operating income (loss):(1)(2)0(1)(7)(10)(13)
Nonoperating income (expense)0(0)(0)(0)(0)(0)0
Investment income, nonoperating      1
Other nonoperating income (expense)0(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before income taxes:(1)(2)0(1)(7)(10)(13)
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Net income (loss):(1)(2)0(1)(7)(10)(13)
Other undisclosed net income attributable to parent    00 
Net income (loss) available to common stockholders, basic:(1)(2)0(1)(7)(10)(13)
Other undisclosed net loss available to common stockholders, diluted      (1)
Net income (loss) available to common stockholders, diluted:(1)(2)0(1)(7)(10)(14)

Comprehensive Income ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
Net income (loss):(1)(2)0(1)(7)(10)(13)
Comprehensive income (loss), net of tax, attributable to parent:(1)(2)0(1)(7)(10)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: